This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winski, S. L. Articles by Ross, D. Search for Related Content PubMed PubMed Citation Articles by Winski, S. L. Articles by Ross, D.

Subcellular Localization of NAD(P)H:quinone Oxidoreductase 1 in Human Cancer Cells¹

Departments of Pharmaceutical Sciences [S. L. W., D. R.] and Physiology and Biophysics [Y. K.], University of Colorado Health Sciences Center, Denver, Colorado 80017, and Imaging Facility, University of Arizona, Tucson, Arizona 85721 [D. L. B.]

NAD(P)H:quinone oxidoreductase 1 (NQO1) is implicated in both chemoprevention and bioactivation of DNA-damaging antitumor agents. NQO1 is mainly cytosolic, but distribution in other cellular compartments, particularly in tumor cells, is poorly defined. Nuclear NQO1 in HT29 human colon carcinoma and H661 human non-small cell lung cancer cells was observed using both confocal microscopy and immunoelectron microscopy. NQO1 was not detected in mitochondria, golgi, or endoplasmic reticulum. In addition, purified intact nuclei from HT29 cells contained immunoreactive NQO1, which was catalytically active as determined by conventional activity assay. In summary, we have confirmed the presence of nuclear NQO1, which has implications for chemoprotection and bioactivation of DNA-damaging antitumor agents.

This article has been cited by other articles:

				M. S. Bentle, K. E. Reinicke, Y. Dong, E. A. Bey, and D. A. Boothman Nonhomologous End Joining Is Essential for Cellular Resistance to the Novel Antitumor Agent, {beta}-Lapachone Cancer Res., July 15, 2007; 67(14): 6936 - 6945. [Abstract] [Full Text] [PDF]

				J. Du, D. H. Daniels, C. Asbury, S. Venkataraman, J. Liu, D. R. Spitz, L. W. Oberley, and J. J. Cullen Mitochondrial Production of Reactive Oxygen Species Mediate Dicumarol-induced Cytotoxicity in Cancer Cells J. Biol. Chem., December 8, 2006; 281(49): 37416 - 37426. [Abstract] [Full Text] [PDF]

				K. S. Ahn, G. Sethi, A. K. Jain, A. K. Jaiswal, and B. B. Aggarwal Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-{kappa}B, I{kappa}B{alpha} Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis J. Biol. Chem., July 21, 2006; 281(29): 19798 - 19808. [Abstract] [Full Text] [PDF]

				G. Li, Z. Liu, E. M. Sturgis, R. M. Chamberlain, M. R. Spitz, and Q. Wei CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 1034 - 1036. [Full Text] [PDF]

				A. Lewis, M. Ough, L. Li, M. M. Hinkhouse, J. M. Ritchie, D. R. Spitz, and J. J. Cullen Treatment of Pancreatic Cancer Cells with Dicumarol Induces Cytotoxicity and Oxidative Stress Clin. Cancer Res., July 1, 2004; 10(13): 4550 - 4558. [Abstract] [Full Text] [PDF]

				J. J. Cullen, M. M. Hinkhouse, M. Grady, A. W. Gaut, J. Liu, Y. P. Zhang, C. J. Darby Weydert, F. E. Domann, and L. W. Oberley Dicumarol Inhibition of NADPH:Quinone Oxidoreductase Induces Growth Inhibition of Pancreatic Cancer via a Superoxide-mediated Mechanism Cancer Res., September 1, 2003; 63(17): 5513 - 5520. [Abstract] [Full Text] [PDF]